SCHEMBL3751053

SCHEMBL3751053

COc1ccc2c(c1)C(=O)N(CC(C)c1cccc3ccccc13)C2C(=O)NCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
POLB P06746 1/20 0.47
SCN9A Q15858 4/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KCNA5 P22460 3/20 0.46
KCNH2 Q12809 2/20 0.46
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
MAPK1 P28482 1/20 0.44
SCN5A Q14524 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
KMT2A Q03164 1/20 0.42
TSHR P16473 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3757666 0.90 KMT2A (0.46) ALDH1A1POLBSCN9ALMNASMN1; SMN2
SCHEMBL3750232 0.88 KCNA5 (0.54) ALDH1A1POLBLMNASMN1; SMN2KCNA5
SCHEMBL3756264 0.87 KCNA5 (0.59) ALDH1A1LMNASMN1; SMN2KCNA5KCNH2
SCHEMBL3744093 0.84 KCNA5 (0.58) ALDH1A1POLBSCN9ALMNASMN1; SMN2
SCHEMBL3751999 0.84 KCNA5 (0.60) ALDH1A1POLBSCN9ALMNASMN1; SMN2
SCHEMBL3762838 0.78 KCNA5 (0.52) ALDH1A1LMNASMN1; SMN2KCNA5KCNH2
SCHEMBL3761468 0.78 KCNH2 (0.54) ALDH1A1POLBSCN9ALMNASMN1; SMN2
SCHEMBL3755278 0.77 KCNA5 (0.75) ALDH1A1POLBSCN9ALMNASMN1; SMN2
SCHEMBL3751916 0.77 KCNA5 (0.47) ALDH1A1KCNA5KCNH2KMT2ATSHR
SCHEMBL3749796 0.76 KCNA5 (0.60) ALDH1A1POLBSCN9ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 ALDH1A1 315/4885POLB 2841/4885SCN9A 119/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 ALDH1A1 310/4885POLB 3428/4885SCN9A 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.